Hair loss hope: new drink targets shedding from popular Weight-Loss meds

NCT ID NCT07484061

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a daily drinkable supplement called Olistic Next Women to see if it can reduce hair loss in women over 35 who are taking GLP-1/GIP weight-loss drugs. Forty participants will be randomly assigned to receive either the supplement or a placebo for 6 months. The main goal is to measure changes in hair shedding using a patient-reported scale and a comb-and-wash test.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TELOGEN EFFLUVIUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

telogen effluvium

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Grupo Dermatologico Y Estetico Pedro Jaen S.A.

    RECRUITING

    Madrid, Madrid, 28006, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••